Description: <p><b>Ginkgetin</b> — a naturally occurring biflavonoid, specifically a dimethylated derivative of amentoflavone, found in <i>Ginkgo biloba</i> and several other plants. It is chemically and pharmacologically distinct from generic Ginkgo biloba extract, EGb 761, ginkgolides, bilobalide, and ginkgolic acids. Ginkgetin has predominantly preclinical anticancer evidence, with reported effects on ferroptosis, apoptosis, cell-cycle arrest, proliferation, invasion, angiogenesis, and chemotherapy sensitivity. Major signaling systems reported to be modulated include NRF2/HO-1, JAK/STAT, PI3K/AKT/GSK-3β, MAPK, Wnt/β-catenin, and TFEB-associated ferroptotic signaling. It should be treated as an isolated natural-product constituent rather than as evidence for the pharmacological effects of ordinary Ginkgo supplementation.</p>
<p><b>Ginkgetin</b> — a naturally occurring biflavonoid, specifically a 3′→8″-linked biflavone and dimethylated derivative of amentoflavone, with the synonym 7,4′-dimethylamentoflavone. It is a small-molecule plant polyphenol rather than a Ginkgo extract and is commonly abbreviated GK. Ginkgetin occurs in <i>Ginkgo biloba</i> leaves and several other plant species. It is chemically and pharmacologically distinct from generic Ginkgo biloba extract, EGb 761, ginkgolides, bilobalide, and ginkgolic acids. Current evidence is predominantly preclinical and supports treating Ginkgetin as a separate isolated natural-product constituent rather than extrapolating its effects to ordinary Ginkgo supplementation.</p>
<p><b>Primary mechanisms (ranked):</b></p>
<ol>
<li>Induction of <b>Ferroptosis</b> through TFEB activation and TFEB–TRIM25-dependent GPX4 ubiquitination and lysosomal degradation, producing loss of GPX4-mediated lipid-peroxide defense.</li>
<li>Disruption of NRF2/HO-1 antioxidant signaling with SLC7A11/GPX4 suppression, GSH depletion, Fe²⁺ accumulation, lipid peroxidation, and increased oxidative stress, particularly during cisplatin treatment.</li>
<li>Suppression of oncogenic JAK2/STAT3 signaling, including SHP-1/PTEN-associated inhibition of STAT3 phosphorylation, proliferation, survival, and tumorigenic signaling.</li>
<li>Suppression of metastatic EMT through AKT/GSK-3β/Snail and Wnt/β-catenin signaling, reducing migration and invasion in experimental lung-cancer models.</li>
<li>Induction of apoptotic signaling through mitochondrial dysfunction, Bax/Bcl-2 modulation, caspase activation, PARP cleavage, and context-dependent MAPK activation.</li>
<li>ROS/H₂O₂-mediated cytotoxicity, with rapid oxidative stress contributing to caspase-dependent apoptosis in susceptible cancer cells.</li>
<li>Cell-cycle inhibition, including G2/M arrest and suppression of proliferative Wnt target genes such as cyclin D1 and survivin.</li>
<li>Anti-angiogenic activity through inhibition of VEGF/VEGFR2-associated AKT, eNOS, ERK, MMP-2, and MMP-9 signaling in experimental vascular models.</li>
<li>Chemosensitization, particularly increased cisplatin responsiveness in experimental lung and cisplatin-resistant cervical cancer through ferroptotic and redox mechanisms.</li>
</ol>
<p><b>Bioavailability / PK relevance:</b> Ginkgetin is highly lipophilic and poorly water-soluble, creating an important oral-delivery limitation. Human pharmacokinetic data for isolated Ginkgetin are essentially absent, and no validated human anticancer plasma target or therapeutic dose has been established. Experimental formulation work, including nanomicelles, is being investigated specifically to improve its systemic exposure. Ginkgetin is also a potent in-vitro inhibitor of UGT1A1, creating a potential drug-interaction concern if pharmacologically relevant systemic concentrations can be achieved.</p>
<p><b>In-vitro vs systemic exposure relevance:</b> Most anticancer studies use isolated Ginkgetin at micromolar concentrations, commonly over prolonged exposures. These concentrations cannot presently be assumed achievable through oral Ginkgo products or conventional Ginkgetin administration because human Cmax data are unavailable and oral bioavailability is poorly characterized. Thus, direct translation of micromolar cell-culture effects to dietary or supplemental Ginkgo exposure is weak.</p>
<p><b>Clinical evidence status:</b> Preclinical only. Evidence includes cancer-cell studies and multiple mouse xenograft or metastasis models, including lung, breast, prostate, medulloblastoma, and cervical-cancer systems. No established human anticancer trials, approved anticancer indication, validated clinical dose, or demonstrated human therapeutic efficacy was identified. FDA substance registration provides a chemical identifier but does not constitute regulatory approval.</p>
<h3>Ginkgetin Cancer-Relevant Mechanisms</h3>
<table border="1" cellpadding="4" cellspacing="0">
<tr>
<th>Rank</th>
<th>Pathway / Axis</th>
<th>Cancer Cells</th>
<th>Normal Cells</th>
<th>TSF</th>
<th>Primary Effect</th>
<th>Notes / Interpretation</th>
</tr>
<tr>
<td>1</td>
<td>STAT3 survival signaling</td>
<td>STAT3 phosphorylation ↓; nuclear STAT3 ↓; STAT3-dependent survival signaling ↓</td>
<td>Not established</td>
<td>R, G</td>
<td>Proliferation ↓; apoptosis ↑</td>
<td>Among the best independently replicated Ginkgetin mechanisms. South Korean studies support inhibition of constitutive and inducible STAT3 signaling in prostate cancer and hematologic cancer models.</td>
</tr>
<tr>
<td>2</td>
<td>Caspase and mitochondrial apoptosis</td>
<td>Caspase-3 ↑; caspase-8 ↑; caspase-9 ↑; Bax ↑; Bcl-2 ↓; Bcl-xL ↓; survivin ↓; apoptosis ↑</td>
<td>Apoptosis effects context-dependent</td>
<td>R, G</td>
<td>Programmed cell death</td>
<td>Supported across multiple cancer models and geographically independent laboratories. ROS-dependent caspase activation was demonstrated in an early Taiwanese ovarian-cancer study.</td>
</tr>
<tr>
<td>3</td>
<td>Cell-cycle regulation</td>
<td>G2 arrest ↑; cyclin D1 ↓; proliferation ↓</td>
<td>Not established</td>
<td>G</td>
<td>Cytostatic growth inhibition</td>
<td>Independent South Korean colorectal-cancer work demonstrated dose-dependent growth inhibition and G2-phase arrest. Other tumor models also report cell-cycle suppression.</td>
</tr>
<tr>
<td>4</td>
<td>ROS and hydrogen peroxide stress</td>
<td>ROS ↑; H₂O₂ ↑; oxidative DNA damage ↑</td>
<td>ROS may ↓ (context-dependent)</td>
<td>P, R</td>
<td>Oxidative stress-mediated apoptosis</td>
<td>In ovarian adenocarcinoma cells, intracellular H₂O₂ increased within approximately 30 minutes; catalase and antioxidant pretreatment partially reduced DNA damage and cytotoxicity. This provides geographically independent evidence predating recent ferroptosis studies.</td>
</tr>
<tr>
<td>5</td>
<td>NRF2 HO-1 SLC7A11 GPX4 ferroptosis</td>
<td>NRF2 ↓; HO-1 ↓; SLC7A11 ↓; GPX4 ↓; GSH ↓; Fe²⁺ ↑; lipid peroxidation ↑; ferroptosis ↑</td>
<td>NRF2 may ↑ in nonmalignant injury models (context-dependent)</td>
<td>R, G</td>
<td>Ferroptotic cell death and chemosensitization</td>
<td>Strong mechanistic evidence exists in lung and cervical-cancer models, particularly with cisplatin, but this evidence is presently concentrated in mainland Chinese research groups and has limited geographically independent replication.</td>
</tr>
<tr>
<td>6</td>
<td>TFEB TRIM25 GPX4 lysosomal degradation</td>
<td>TFEB activation ↑; TRIM25-mediated GPX4 ubiquitination ↑; GPX4 lysosomal degradation ↑; ferroptosis ↑</td>
<td>Not established</td>
<td>R, G</td>
<td>Ferroptosis</td>
<td>Recent mechanistically detailed pathway in EGFR wild-type lung adenocarcinoma. Potentially important, but independent replication is currently limited; therefore ranked below the more broadly replicated STAT3, apoptosis, cell-cycle, and ROS mechanisms.</td>
</tr>
<tr>
<td>7</td>
<td>Wnt β-catenin and EMT signaling</td>
<td>Wnt β-catenin signaling ↓; Snail ↓; EMT ↓; migration ↓; invasion ↓</td>
<td>Not established</td>
<td>R, G</td>
<td>Metastatic phenotype suppression</td>
<td>Supported in medulloblastoma and lung-cancer models. Evidence is biologically coherent but remains more geographically concentrated than the higher-ranked mechanisms.</td>
</tr>
<tr>
<td>8</td>
<td>AKT GSK-3β Snail signaling</td>
<td>AKT signaling ↓; GSK-3β-associated EMT signaling ↓; Snail ↓; migration ↓; invasion ↓</td>
<td>Not established</td>
<td>R, G</td>
<td>Migration and invasion ↓</td>
<td>Primarily supported by lung adenocarcinoma studies. Closely overlaps with Wnt and EMT modulation and should be interpreted as a context-dependent metastatic signaling mechanism.</td>
</tr>
<tr>
<td>9</td>
<td>Estrogen receptor and PFKFB3 signaling</td>
<td>ERα signaling ↓; PFKFB3-associated survival signaling ↓; viability ↓</td>
<td>Not established</td>
<td>G</td>
<td>ER-positive breast-cancer growth inhibition</td>
<td>Supported by an independent South Korean study in MCF-7 and T-47D breast-cancer cells. Likely tumor-subtype specific rather than a universal Ginkgetin mechanism.</td>
</tr>
<tr>
<td>10</td>
<td>VEGF VEGFR2 angiogenic signaling</td>
<td>Angiogenesis ↓</td>
<td>VEGFR2 signaling ↓; AKT ↓; eNOS ↓; ERK ↓; MMP-2 ↓; MMP-9 ↓</td>
<td>R, G</td>
<td>Anti-angiogenic activity</td>
<td>Experimental endothelial and tumor models support anti-angiogenic activity, but independent geographic replication is limited and some evidence involves combination treatment.</td>
</tr>
<tr>
<td>11</td>
<td>Cisplatin chemosensitization</td>
<td>Cisplatin sensitivity ↑; ferroptosis ↑; apoptosis ↑</td>
<td>Normal-tissue selectivity not established</td>
<td>G</td>
<td>Drug-response enhancement</td>
<td>Preclinical lung and cervical-cancer studies indicate increased cisplatin responsiveness, principally through ferroptotic and redox pathways. No human clinical validation has been established.</td>
</tr>
<tr>
<td>12</td>
<td>Clinical Translation Constraint</td>
<td>Effective experimental exposure generally micromolar; human therapeutic exposure unknown</td>
<td>Potential metabolic drug interactions; normal-tissue exposure insufficiently characterized</td>
<td>G</td>
<td>Limits clinical extrapolation</td>
<td>Poor aqueous solubility, uncertain human bioavailability, absence of validated human pharmacokinetic targets, geographic concentration of several newer mechanistic findings, and lack of clinical cancer trials substantially limit translation.</td>
</tr>
</table>
<p><b>TSF:</b> P: 0–30 min R: 30 min–3 hr G: >3 hr</p>